Homepage - Full Width Slider

Immunotherapy
- the future of cancer therapy
Results from Phase I Trial of TG01 and gemcitabine in resected pancreatic cancer
presented at CIMT, Germany, 6.-8. May

Error message

  • Warning: array_merge() [function.array-merge]: Argument #1 is not an array in pe_slider_block_view() (line 552 of /home/4/t/targovax/www/sites/all/modules/bigwig_tools/pe_slider/pe_slider.module).
  • Warning: array_merge() [function.array-merge]: Argument #1 is not an array in pe_slider_block_view() (line 552 of /home/4/t/targovax/www/sites/all/modules/bigwig_tools/pe_slider/pe_slider.module).

Targovax on the NOTC-list

Targovax has completed a capital increase of 70 MNOK (11.5 MUSD), and is now registered on the NOTC trading list. 
Read more

Targovax is now hiring

Targovax is expanding its operations and is now hiring a Senior Manager Quality Assurance, and Project Manager Drug Development.
Read more

Clinical Phase I Results

Clinical Phase I Results for TG01 presented at CIMT.
Read more